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Background: We aimed to identify the 1-year relapse rate and risk factors for patients with
pulmonary tuberculosis (TB) treated with a 6-month daily regimen.
Methods: A total of 317 patients with pan-susceptible pulmonary TB who completed a 6-month
daily course of treatment [2HRZ(E)/4HR(E)] were retrospectively analyzed.
Results: The mean age was 50.0  16.8 years and men were predominant (61.2%). All of 137
adults tested for HIV were negative. Six (1.9%) cases relapsed within one year. Relapse rate
was higher in patients with a positive culture after 2 months of treatment (10.0%,
p Z 0.049) and in patients with both a positive culture after 2 months of treatment and cavi-
tation on initial chest radiograph (18.2%, p Z 0.015), whereas relapse rate in patients with
cavitation alone was comparable to that of the total population (2.7%). Among various risk fac-
tors known to increase risk of relapse, the combined variable of cavitation and positive culture
at 2 months (OR Z 15.56, 95% CI 2.56e98.71, p Z 0.003) was only associated with increased
relapse rate in a multivariate analysis.
Conclusions: Even with a 6-month daily treatment regimen throughout the intensive and contin-
uation phases, the relapse ratewas unacceptably high in patientswith both a positive culture at 2
months of treatment and cavitation on baseline chest radiography. Intensification of treatment,
such as an extension of treatment duration, should be considered in this category of patients.
ª 2014 Elsevier Ltd. All rights reserved.ulmonary & Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-
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One of the problems of tuberculosis (TB) control is the fact
that patients who were successfully treated can relapse,
necessitating a second treatment. Reported rates of
relapse after standard 6-month treatment for drug-
susceptible pulmonary TB have ranged from 1 to 2% at 24
months [1]. Variable parameters such as host factors [2e5],
disease factors [6e9], and treatment factors [8,10,11] have
been identified as being related to increased relapse rates.
Among these, the most important factors are probably
positive acid-fast bacilli (AFB) culture on completion of the
2-month intensive phase and cavitation on initial chest
radiograph (CXR) [1,6,8,13]. Based on the report that the
coexistence of these two factors can increase the risk of
relapse up to approximately 20% [6], the American Thoracic
Society (ATS) has recommended the minimum duration of
treatment should be extended to 9 months for patients with
these two risk factors [14].
According to World Health Organization (WHO) guide-
lines, a daily dosing frequency throughout the course of
therapy for new patients with pulmonary TB is optimal [15].
However, in many countries, a 6-month standard regimen is
given three times weekly throughout therapy or only in the
continuation phase. ATS guidelines regarding the extension
of treatment duration to 9 months are also based on a study
which revealed increased relapse rate in patients treated
with a twice a week regimen for continuation phase
treatment [6]. On the other hand, according to Korean
national TB guidelines, the recommended treatment for
patients with TB is a 6-month daily regimen throughout the
course of therapy [16]. Hence, we questioned whether the
relapse rate is still high in pulmonary TB patients who had
both a 2-month positive culture after treatment initiation
and cavitation at baseline and in whom a 6-month short-
course treatment was taken daily throughout the course
of therapy.
In the present study, we aimed to identify the 1-year
relapse rate and associated risk factors for patients with
drug-susceptible pulmonary TB treated with a standard 6-
month daily regimen in South Korea, an intermediated TB-
burden country.
Methods
Study subjects
Study subjects were selected from the TB registry of Asan
Medical Center, a 2700-bed referring hospital in Seoul, in
South Korea and who were treated between January 2000
and December 2010. Enrollment criteria were as follows: 1)
culture-confirmed, pan-susceptible pulmonary TB, 2)
follow-up data were available until 1 year after treatment
completion, 3) treatment with a standard 6-month daily
regimen comprised of 2 months of isoniazid/rifampicin/
pyrazinamide/ethambutol and 4 months of isoniazid/
rifampicin [2HRZ(E)/4HR(E)], and 4) 2-month culture con-
version results were available. In this study subjects,
medications were taken daily (7 day/week) throughout the
course of therapy according to Korean national TB guide-
lines [16]. Ethambutol was taken throughout the course oftherapy or until the rapid or conventional drug suscepti-
bility testing (DST) revealed drug-susceptible results ac-
cording to the attending physician’s preference. Directly
observed treatment (DOT) was not followed, instead
private-public mix cooperation (PPM) nurses monitored the
treatment courses [17]. Study subjects were recommended
to revisit the clinic at 3e4 months and 12 months after
treatment completion. A CXR was taken each time
regardless of the presence of symptoms, and sputum AFB
smear/culture tests were performed if the CXR showed any
suspicion of TB relapse. Relapse was defined as a circum-
stance in which a patient became or remained culture-
negative while receiving anti-TB drugs, but at some point
after the completion of therapy became either culture-
positive again or experienced clinical, histological and/or
radiographic features consistent with active TB, including
an appropriate response to retreatment [1].
Patients’ demographic and clinical data, TB treatment
history, treatment outcomes and 1-year relapse rate were
retrospectively reviewed. We followed WHO definitions for
treatment outcomes [14]. The Institutional Review Board of
Asan Medical Center approved this study (2013-0019).
Radiographic severity was evaluated using the recom-
mendations of the National Tuberculosis Association of the
United States [18].
Bacteriological study
AFB smears were examined by ZiehleNeelsen staining. AFB
culture was carried out using solid media alone until July
2007 and then using both solid and liquid media (BACTEC
960 Mycobacterial Growth Indicator Tube; Becton Dick-
inson, Sparks, MD, USA) thereafter. Conventional DST was
performed using the absolute concentration method with
Lowe¨nsteineJensen media at the Korean Institute of
Tuberculosis. Pyrazinamide susceptibility was determined
using the pyrazinamidase test. Rapid molecular DSTs tar-
geting both isoniazid and rifampicin resistance were also
applied in a subset of patients: MTB-Rifa assay (M&D,
Wonju, Korea) or GenoType MTBDRplus assay (Hain Life-
science, Nehren, Germany).
Statistical analysis
Comparisons between groups were made using the x2 tests
for categorical variables. Odds ratio and multiple logistic
regression analysis were used to calculate adjusted risk.
Independent variables were selected on the basis of their
statistical significance. All tests of significance were two
sided; p < 0.05 was considered statistically significant. All
statistical analyses were performed using SPSS software
(version 12.0; SPSS Inc., Chicago, Illinois, USA).
Results
Characteristics of study subjects
Among 836 patients with pan-susceptible pulmonary TB
whose 1 year follow up data were available, 519 patients
were excluded due to various reasons and 317 patients
Table 1 Clinical characteristics of 317 patients with pul-
monary tuberculosis.a
Characteristics
Age (yr) 50.0  16.8
Gender (M/F) 194/123
BMI (kg/M2) 21.5  3.1
Underlying diseases
Diabetes mellitus 5 (1.6%)
Hypertension 36 (11.4%)
Malignancy 15 (4.7%)
Previous history of TB treatment 54 (17.0%)
Positive AFB smear at treatment initiation 126 (39.7%)
Radiologic severity
Minimal 218 (68.6%)
Moderately advanced 89 (28.1%)
Far advanced 10 (3.2%)
Bilateral disease 125 (39.4%)
Cavitary disease 76 (24.0%)
Positive AFB culture at 2 months of treatment 20 (6.3%)
Cavitation and positive AFB culture at 2 months 11 (3.5%)
Abbreviations: BMI Z body mass index; TB Z tuberculosis;
AFB Z acid-fast bacillus.
a Means  standard deviations (SD) or number (%) of subjects.
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enrollment criteria (Fig. 1). Demographic and clinical
characteristics of the total population are shown in Table 1.
Among 117 patients whose AFB culture was performed
using solid media alone, three patients (2.6%) showed
positive culture results at 2 months after treatment initia-
tion. In the remaining 200 patients in whom AFB culture was
carried out using both solid and liquid media, 17 patients
(8.5%) had positive 2-month culture (p Z 0.053).
All patientswere recorded tohave goodadherence to their
TB medication regimen. The median duration of ethambutol
treatment was 98 (range 6e182) days. Human immunodefi-
ciency virus (HIV) tests were conducted in 137 (43.2%) pa-
tients with none showing positive results. Patients who were
not tested for HIV did not have any clinical indications of HIV
infection at initiation of treatment or during follow-up.
Treatment outcome and relapse
According to enrollment criteria, treatment success was
achieved in all patients: cure in 238 (75.1%) and treatment
completion in 79 (24.9%).
Asawhole, six (1.9%) cases that relapsedwithin 1 year after
treatment completion were identified. The period from the
completion of treatment to the diagnosis of relapse had a
median of 110 days (range, 52e271 days). All relapses were
confirmedbacteriologically andeachof the six clinical isolates
was susceptible to all anti-TB drugs. Three (1.3%) cases of
relapse were identified among 238 patients with cure and
another 3 (3.8%) cases among 79 patients with treatment
completion (pZ 0.166). When relapse rate was analyzed ac-
cording to the presence of specified risk factors, relapse rate
was significantly higher in two subgroups: patients with a
positive culture after 2 months of treatment (relapse rate
10.0%, p Z 0.049) and patients who had both cavitation on
initial CXR and positive 2-month culture (relapse rate 18.2%,
pZ 0.015) (Table 2).
Risk factors for relapse
Among various risk factors, only two variables (positive AFB
culture at 2 months of treatment and cavitation with pos-
itive AFB culture at 2 months) were shown to be signifi-
cantly associated with increased risk of relapse in a
univariate analysis (Table 3, OR Z 8.12, 95% CI 1.40e47.44
and OR Z 16.78, 95% CI 2.71e103.79, respectively).
In multivariate analyses, only the combined variable of a
positive culture at 2 months and cavitation on the initialFigure 1 Screening and enrollment of studyCXR (OR Z 15.56, 95% CI 2.56e98.71) was independently
associated with increased risk of relapse (Table 3).Discussion
ATS guidelines recommend extending the continuation
phase from 4 to 7 months in pulmonary TB patients with
both a positive 2-month culture and cavitation [14]. The
supporting evidence for this recommendation has been
criticized as weak because of the fact that it was primarily
based on a study which revealed increased risk of relapse in
patients treated with a twice a week regimen of isoniazid
and rifampicin for continuation phase treatment [6].
Currently, WHO guideline does not recommend a twice a
week regimen [15]. A three times a week or daily regimen
in the continuation phase may decrease the relapse rate.
Hence, many guidelines, including WHO guideline, do not
recommend extending the treatment duration up to 9
months for patients with pulmonary TB who have a positive
culture at 2 months after treatment initiation and cavita-
tion on initial CXR.patients Abbreviations: TB Z tuberculosis.
Table 2 Rate of 1 year relapse by presence of specified
risk factor.a
Relapse P-value
Whole population (n Z 317) 6 (1.9%)
Age  60 yrs (n Z 105) 3 (2.9%) 0.402
Male gender (n Z 194) 3 (1.5%) 1.000
BMI < 18.5 Kg/M2 (n Z 49) 1 (2.0%) 1.000
Diabetes mellitus (n Z 5) 0 1.000
Previous history of TB treatment
(n Z 54)
1 (1.9%) 1.000
Positive AFB smear at treatment
initiation (n Z 126)
2 (1.6%) 1.000
Moderately to far advanced disease
(n Z 99)
3 (3.0%) 0.381
Bilateral disease (n Z 125) 2 (1.6%) 1.000
Cavitary disease (n Z 76) 2 (2.7%) 0.633
Positive AFB culture at 2
months of treatment (n Z 20)
2 (10.0%) 0.049
Cavitation and positive AFB
culture at 2 months (n Z 11)
2 (18.2%) 0.015
Abbreviations: BMI Z body mass index; AFB Z acid-fast
bacillus.
a Values are number (%).
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relapse rate was significantly higher in patients with both
risk factors (presence of a positive culture at 2 months of
treatment and cavitation on CXR) who successfully
completed 6 months of daily therapy and, 2) extending
total treatment duration from 6 to 9 months may reduce
the relapse rate in these patients. Thus, the present study
provides supporting evidence for ATS guidelines to extent
the duration of treatment for this subset of patients even if
a standard daily regimen is used.
Perrin et al. previously reported that the change in
sputum mycobacterial load showed separate parallel lines
in response to anti-TB treatment depending on the initial
sputum mycobacterial load in patients with cavitary TB
[19]. This finding suggests that the duration of treatment
needs be extended in those patients with a high initialTable 3 Univariate and multivariate analysis of risk factors for
Variables Univariate
OR (95% CI)
Age  60 yrs 2.05 (0.41
Male gender 0.94 (0.15
BMI < 18.5 Kg/M2 1.15 (0.13
Diabetes mellitus 0.98 (0.97
Previous history of TB treatment 0.97 (0.11
Positive AFB smear at treatment initiation 1.33 (0.24
Moderately to far advanced disease 2.50 (0.50
Bilateral disease 0.76 (0.14
Cavitary disease 1.60 (0.29
Positive AFB culture at 2 months of treatment 8.12 (1.40
Cavitation and positive AFB culture at 2 months 16.78 (2.71
Abbreviations: OR Z odds ratio; CI Z confidence interval; BMI Z bomycobacterial load. Among various risk factors known to
increase the risk of relapse, such as patients’ sex [2],
recent smoking [3], DM [4], HIV infection [5], cavitation
[4,6,9], low body weight [6], bilateral disease [6], radio-
logic severity [2,9], positive AFB culture at 2 months [6,7],
treatment regimen and dosing schedule [1,8e12], the most
well-known and consistent risk factors are a positive AFB
culture on completion of the 2-month of intensive phase
treatment and cavitation on initial CXR [1,6,8,13], probably
because these two parameters are associated with a higher
initial mycobacterial load. In contrast to previous studies,
which reported increased risk of relapse in patients with a
positive 2-month sputum culture or cavitation, we failed to
find a significant association between 1-year relapse and
only one of these risk factors in a multivariate analysis.
However, considering the high relapse rate in patients with
a positive culture at 2 months of treatment and without
cavitation, treatment may be extended in a subset of these
patients, for example, in patients with extensive disease or
with high grade culture results, since a positive sputum
culture at 2 months is known to be associated with the
inadequate sterilizing ability of drugs used in the intensive
phase [20].
According to recent WHO guidelines [15], the optimal
dosing frequency for new patients with pulmonary TB is
daily throughout the course of therapy. The guidelines also
recommend: 1) the daily intensive phase be followed by a
three times weekly continuation, provided that each dose is
directly observed and 2) a three times weekly regimen may
be considered throughout therapy, provided that DOT is
performed and the patient is not living in an HIV-prevalent
setting. In South Korea, daily treatment throughout the
course of therapy has been recommended since the stan-
dard 4-drug regimen being introduced [21]. While etham-
butol had been recommended throughout the 6-month
course because of high rates of primary drug resistance
[21], current revised guidelines now recommend omitting
ethambutol once DST has revealed drug-susceptible TB
[16]. In contrast to ATS guidelines, the recently updated
Korean guidelines for TB [16] do not specifically mention
whether the treatment duration should be extended or not
in those patients with a positive culture at 2 months of1 year relapse.
analysis Multivariate analysis
p-Value OR (95% CI) p-Value
e10.33) 0.385 2.31 (0.43e12.50) 0.330
e5.68) 0.941 0.64 (0.12e3.44) 0.602
e10.53) 0.901 0.60 (0.19e18.46) 0.597
e1.00) 0.908 0.78 (0.62e1.23) 0.897
e8.50) 0.981 0.56 (0.06e5.81) 0.630
e7.35) 0.747 0.59 (0.10e3.61) 0.567
e12.63) 0.268 3.08 (0.40e23.78) 0.282
e4.21) 0.749 0.72 (0.12e4.30) 0.722
e8.92) 0.591 1.02 (0.16e6.47) 0.981
e47.44) 0.021 7.08 (1.25e42.23) 0.068
e103.79) 0.002 15.56 (2.56e98.71) 0.003
dy mass index; AFB Z acid-fast bacillus.
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whether the relapse rate remains high in patients treated
with daily treatment throughout the course of therapy.
Based on our current results, it would be reasonable to
conclude that intensification of therapy, such as prolonga-
tion of treatment duration, should be considered for these
patients in South Korea as well considering the unaccept-
ably high rate of relapse even in those patients who
completed a 6-month daily regimen in present study.
A total of 161 patients were treated with a standard 9-
month daily regimen [2HRZ(E)/7HR(E)] in our study. Even
though a 6-month regimen is the current worldwide stan-
dard therapy for drug-susceptible pulmonary TB, in private-
sector practice in Korea, some physicians prescribe a 4-
drug, short-course regimen for 9 months. The reason for
such a change may be concerns of delayed CXR response,
cavitation on initial CXR, and/or delayed sputum AFB smear
or culture conversion, and so on. Interestingly, among these
161 patients, nine (5.6%) had both a positive culture on
completion of the 2-month intensive phase and cavitation
on initial CXR without a relapse during a 1-year follow-up
period. Even though this is a retrospective study and the
relapse rate did not differ statistically between 6-month
and 9-month treatment groups, this may be due to the
small number of study subjects. Further prospective studies
enrolling a larger number of patients to compare 6-month
and 9-month regimen in these specific patient groups could
help resolve this issue.
According to our enrollment criteria, only patients suc-
cessfully completing a 6-month standard daily regimen
were included, indicating that only patients with good
compliance were selected. Although adherence to treat-
ment was not confirmed by DOT in this study, specially
trained PPM nurses monitored our patients. Korean national
TB guidelines have not yet adopted DOT, instead,
government-supported PPM nurses monitor the course of
patients’ treatment. The roles of PPM nurses in TB care are:
1) educate patients with TB regarding TB, anti-TB therapy,
possible adverse events of anti-TB therapy, and their
management, 2) contact investigation of household and
non-household contacts, 3) encourage patients to keep
regular hospital appointments, 4) check drug compliance
and for any adverse events, and 5) urge patients who
missed their appointment, to visit a hospital. According to a
report in Korea, PPM-monitored patients showed a signifi-
cantly higher treatment success rate (93.5%) compared
with self-administered patients (77.9%) [17].
This study has several limitations. First, it was a retro-
spective study with a relatively small number of patients
from a single referral center. Second, in about a third of our
patients, solid media alone was used for AFB culture. As
seen in this study and others [22,23], positive culture rates
at treatment initiation and at 2 months after treatment
initiation are higher when using both solid and liquid media,
rather than using solid media alone. However, when the
analysis was restricted to 218 patients in whom AFB culture
had been identified in the solid media, a multivariate
analysis showed the same findings (data not shown). In
addition, in relapsed patients, DNA fingerprinting analysis
for both initial bacilli and relapsed bacilli was not per-
formed. Accordingly, we could not definitively confirm
whether the recurrent TB was due to relapse of the originalbacilli or due to reinfection of with another bacilli [24].
However, given the timing of recurrence within one year of
treatment completion, we considered all TB recurrences as
relapses [3,14]. Finally, in our study, HIV testing was con-
ducted in only 137 (43.2%) patients, all with negative re-
sults. Since South Korea is a very low HIV-burden country,
doctors may not be concerned with possibility of HIV
infection in patients with TB. Lee et al. showed that only
0.05% (77/152,887) of patients with TB were HIV-positive
between 2001 and 2005 in Korea [25]. In our study, pa-
tients who were not tested for HIV did not have any clinical
indications of HIV infection at initiation of treatment or
during follow-up. Considering these findings, our study re-
sults may be applicable only to HIV-negative TB patients.
In conclusion, even with a standard 6-month daily 4-drug
treatment throughout the intensive and continuation
phase, the relapse rate was unacceptably high in patients
with both a positive culture at 2 month of treatment and
with cavitation on baseline CXR. Intensification of treat-
ment, such as an extension of the duration of drug therapy,
should be considered for this category of patients.Conflict of interest statement
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